Alps Advisors Inc. raised its position in shares of Minerva Neurosciences, Inc (NASDAQ:NERV) by 10.6% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 33,131 shares of the biopharmaceutical company’s stock after buying an additional 3,187 shares during the period. Alps Advisors Inc. owned 0.09% of Minerva Neurosciences worth $293,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. ClariVest Asset Management LLC boosted its stake in Minerva Neurosciences by 1.0% in the first quarter. ClariVest Asset Management LLC now owns 29,200 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 300 shares during the period. TD Asset Management Inc. boosted its stake in Minerva Neurosciences by 1.3% in the first quarter. TD Asset Management Inc. now owns 27,100 shares of the biopharmaceutical company’s stock worth $220,000 after buying an additional 357 shares during the period. Bank of New York Mellon Corp boosted its stake in Minerva Neurosciences by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 80,201 shares of the biopharmaceutical company’s stock worth $649,000 after buying an additional 1,286 shares during the period. Russell Investments Group Ltd. boosted its stake in Minerva Neurosciences by 54.6% in the second quarter. Russell Investments Group Ltd. now owns 15,794 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 5,579 shares during the period. Finally, Rhumbline Advisers boosted its stake in Minerva Neurosciences by 35.9% in the second quarter. Rhumbline Advisers now owns 27,082 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 7,150 shares during the period. Hedge funds and other institutional investors own 69.29% of the company’s stock.

Shares of Minerva Neurosciences, Inc (NASDAQ NERV) opened at 6.10 on Wednesday. Minerva Neurosciences, Inc has a 12-month low of $5.55 and a 12-month high of $14.92. The company has a 50-day moving average price of $7.14 and a 200 day moving average price of $8.08. The firm’s market capitalization is $259.30 million.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.07. During the same quarter in the prior year, the company earned ($0.18) EPS. On average, equities analysts expect that Minerva Neurosciences, Inc will post ($1.19) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/30/alps-advisors-inc-has-293000-position-in-minerva-neurosciences-inc-nerv.html.

A number of equities research analysts have recently commented on the company. Zacks Investment Research upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research report on Tuesday, August 22nd. BidaskClub cut Minerva Neurosciences from a “hold” rating to a “sell” rating in a research report on Monday, July 24th. ValuEngine upgraded Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, May 23rd. Finally, JMP Securities restated an “outperform” rating and set a $20.00 target price (up from $17.00) on shares of Minerva Neurosciences in a research report on Thursday, June 1st. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $14.58.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

Want to see what other hedge funds are holding NERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Minerva Neurosciences, Inc (NASDAQ:NERV).

Institutional Ownership by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Stock Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related stocks with our FREE daily email newsletter.